Western Wealth Management LLC Increases Stock Position in Amgen Inc. $AMGN

Key Points

• Western Wealth Management increased its Amgen stake by 137.5% in the first quarter, owning 10,207 shares worth approximately $3.59 million. Hedge funds and institutional investors collectively hold 76.5% of AMGN shares.
• Analyst sentiment remains mixed, with an overall “Hold” rating and an average price target of $357, below the stock’s reported $385.16 price.
• Amgen exceeded quarterly earnings expectations, reporting $5.15 in EPS and $8.62 billion in revenue, while declaring a quarterly dividend of $2.52 per share, representing an annualized yield of about 2.6%.

Western Wealth Management LLC lifted its position in shares of Amgen Inc. (NASDAQ:AMGN - Free Report) by 137.5% during the first quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 10,207 shares of the medical research company's stock after purchasing an additional 5,910 shares during the period. Western Wealth Management LLC's holdings in Amgen were worth $3,591,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in AMGN. Anfield Capital Management LLC lifted its position in shares of Amgen by 1,000.0% during the 4th quarter. Anfield Capital Management LLC now owns 77 shares of the medical research company's stock worth $25,000 after buying an additional 70 shares in the last quarter. Dogwood Wealth Management LLC boosted its stake in shares of Amgen by 275.0% in the 4th quarter. Dogwood Wealth Management LLC now owns 75 shares of the medical research company's stock worth $25,000 after buying an additional 55 shares during the last quarter. Tower View Wealth Management LLC grew its holdings in shares of Amgen by 331.6% in the first quarter. Tower View Wealth Management LLC now owns 82 shares of the medical research company's stock valued at $29,000 after acquiring an additional 63 shares in the last quarter. Manning & Napier Advisors LLC grew its holdings in shares of Amgen by 49.2% in the fourth quarter. Manning & Napier Advisors LLC now owns 97 shares of the medical research company's stock valued at $32,000 after acquiring an additional 32 shares in the last quarter. Finally, Ares Financial Consulting LLC purchased a new stake in shares of Amgen during the fourth quarter valued at approximately $34,000. 76.50% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of analysts recently commented on the company. Guggenheim lifted their price target on Amgen from $340.00 to $343.00 and gave the stock a "neutral" rating in a report on Monday, July 13th. Weiss Ratings downgraded Amgen from a "buy (b)" rating to a "buy (b-)" rating in a research note on Wednesday, July 15th. Morgan Stanley decreased their target price on Amgen from $340.00 to $333.00 and set an "equal weight" rating for the company in a research report on Wednesday, July 8th. Royal Bank Of Canada reiterated a "positive" rating on shares of Amgen in a research note on Thursday, June 18th. Finally, Mizuho boosted their price target on shares of Amgen from $295.00 to $303.00 and gave the stock a "neutral" rating in a report on Tuesday, June 16th. Two analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, fifteen have assigned a Hold rating and two have given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $357.00.

Amgen Price Performance

Shares of NASDAQ AMGN opened at $385.16 on Friday. The company has a current ratio of 1.26, a quick ratio of 1.01 and a debt-to-equity ratio of 5.65. The stock has a fifty day simple moving average of $356.60 and a two-hundred day simple moving average of $353.77. Amgen Inc. has a 1-year low of $269.77 and a 1-year high of $398.00. The firm has a market cap of $207.87 billion, a price-to-earnings ratio of 26.80, a price-to-earnings-growth ratio of 3.92 and a beta of 0.41.

Amgen (NASDAQ:AMGN - Get Free Report) last issued its earnings results on Thursday, April 30th. The medical research company reported $5.15 earnings per share (EPS) for the quarter, beating the consensus estimate of $4.77 by $0.38. Amgen had a return on equity of 137.41% and a net margin of 20.96%.The firm had revenue of $8.62 billion for the quarter, compared to analyst estimates of $8.58 billion. During the same period in the previous year, the company posted $4.90 earnings per share. The business's revenue was up 5.8% on a year-over-year basis. Analysts anticipate that Amgen Inc. will post 22.31 earnings per share for the current year.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, September 11th. Investors of record on Friday, August 21st will be paid a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.6%. The ex-dividend date is Friday, August 21st. Amgen's payout ratio is currently 70.15%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: The European Medicines Agency’s CHMP issued a positive opinion recommending broader use of Repatha to reduce cardiovascular risk in high-risk adults without a prior heart attack or stroke. The recommendation, based on Phase 3 data showing fewer major cardiovascular events, could expand Repatha’s addressable market in Europe. Amgen Wins Backing in Europe for Broader Repatha Use
• Positive Sentiment: Amgen declared a quarterly dividend of $2.52 per share, payable September 11 to shareholders of record on August 21. The ongoing payout, equivalent to $10.08 annually and an indicated yield of about 2.6%, supports the stock’s income appeal and signals continued confidence in cash generation. Amgen Announces 2026 Third Quarter Dividend
• Positive Sentiment: Amgen launched its first Amgen Scholars Program in India at IIIT Hyderabad. Although not a near-term financial driver, the initiative may strengthen the company’s research talent pipeline and scientific relationships. First Amgen Scholars Program in India Launches
• Neutral Sentiment: Wall Street’s attention is centered on second-quarter results. Amgen has a history of earnings beats, but investors will scrutinize product-sales trends, guidance and progress on MariTide, making the report a significant near-term catalyst. Amgen Q2 Earnings Preview
• Negative Sentiment: Barclays raised its price target to $360 but retained a Hold rating. With the target below the recent trading level, the update reinforces concerns that much of Amgen’s positive outlook may already be reflected in the shares. Barclays Boosts Amgen Price Target

Insider Buying and Selling

In other Amgen news, SVP Nancy A. Grygiel sold 1,237 shares of the company's stock in a transaction dated Monday, May 4th. The shares were sold at an average price of $323.73, for a total transaction of $400,454.01. Following the sale, the senior vice president directly owned 7,009 shares of the company's stock, valued at $2,269,023.57. This represents a 15.00% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. 0.85% of the stock is currently owned by company insiders.

Amgen Company Profile

Amgen Inc NASDAQ: AMGN is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen's work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen's commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.

Want to see what other hedge funds are holding AMGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Amgen Inc. (NASDAQ:AMGN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.